The WHO considers dim MPO expression (i.e., not reaching the 50% intensity threshold of neutrophils) to be controversial, especially in cases where the immunophenotype of the aberrant blast population aligns with that of B-lymphoblastic leukemia/lymphoma (i.e., the blast population shows relatively homogenous expression of B-lineage markers). This evidence concerns the gene MPO and lymphoma.